Pivot has acquired worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid, cannabidiol (CBD) and tetrahydrocannabinol (THC) based products.

This water-soluble micelle oral formulation technology provides significantly higher bioavailability and stability as compared to other alternative oil-based formulations.

SOLMIC RESEARCH GmbH

 

Technology Overview


Solmic Solubilisation Technology Platform:

Pivot has acquired worldwide rights from Solmic GmbH (a privately / held German company) for the development and commercialization of “Solmic Solubilisation Technology Platform” for defined cannabinoids or cannabinoid-containing extracts. The formulation technology provides significantly higher bioavailability and stability compared to alternative oil-based formulations. This technology strongly enhances the uptake of water insoluble ingredients by keeping lipid soluble compounds trapped in micelles and thus increase significantly the uptake of these molecules from the intestine.

Solmic’s technology allows active ingredients to become water soluble without changing their composition and nature. Solubilized substances that are packed in micelles are protected from degradation from light, stomach acid, and from enzymes released in the intestinal tract. In addition, micelles can mask unpleasant smells and tastes. The micellisation process results in a stable, homogenous and transparent mixture, thereby significantly increasing uptake from the gut into the blood system of fat soluble ingredients, resulting in greater bioavailability